

Ylenia Ingrasciotta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6964702/publications.pdf>

Version: 2024-02-01

30
papers

620
citations

623574

14
h-index

610775

24
g-index

31
all docs

31
docs citations

31
times ranked

906
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel Therapeutic Approaches to Psoriasis and Risk of Infectious Disease. <i>Biomedicines</i> , 2022, 10, 228.	1.4	16
2	Efficacy of Systemic Biologic Drugs in Pediatric Psoriasis: Evidence From Five Selected Randomized Clinical Trials. <i>Frontiers in Pharmacology</i> , 2022, 13, 847308.	1.6	5
3	Direct healthcare costs of chronic kidney disease management in Italy: What cost savings can be achieved with higher biosimilar uptake and more appropriate use of erythropoiesis-stimulating agents?. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 65-77.	0.9	3
4	Psoriasis and psoriasiform reactions secondary to immune checkpoint inhibitors. <i>Dermatologic Therapy</i> , 2021, 34, e14830.	0.8	18
5	Comparison of Direct Oral Anticoagulant Use for the Treatment of Non-Valvular Atrial Fibrillation in Pivotal Clinical Trials vs. the Real-World Setting: A Population-Based Study from Southern Italy. <i>Pharmaceuticals</i> , 2021, 14, 290.	1.7	1
6	Characteristics and Absolute Survival of Metastatic Colorectal Cancer Patients Treated With Biologics: A Real-World Data Analysis From Three European Countries. <i>Frontiers in Oncology</i> , 2021, 11, 630456.	1.3	7
7	Kidney Disease in Diabetic Patients: From Pathophysiology to Pharmacological Aspects with a Focus on Therapeutic Inertia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4824.	1.8	35
8	Safety and potential interaction of immunosuppressive drugs for the treatment of inflammatory bowel disease in elderly patients. <i>Minerva Gastroenterology</i> , 2021, , .	0.3	1
9	Are Patients with Psoriasis and Psoriatic Arthritis Undertreated? A Population-Based Study from Southern Italy. <i>Journal of Clinical Medicine</i> , 2021, 10, 3431.	1.0	14
10	Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: The VALORE Project. <i>BioDrugs</i> , 2021, 35, 749-764.	2.2	16
11	Cancer Patients at Risk for Medication-Related Osteonecrosis of the Jaw. A Case and Control Study Analyzing Predictors of MRONJ Onset. <i>Journal of Clinical Medicine</i> , 2021, 10, 4762.	1.0	8
12	Neoplastic Implications in Patients Suffering from Hidradenitis Suppurativa under Systemic Treatments. <i>Biomedicines</i> , 2021, 9, 1594.	1.4	8
13	In Search of Predictors of Switching Between Erythropoiesis-Stimulating Agents in Clinical Practice: A Multi-Regional Cohort Study. <i>BioDrugs</i> , 2020, 34, 55-64.	2.2	2
14	Real World Use of Antidiabetic Drugs in the Years 2011-2017: A Population-Based Study from Southern Italy. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 9514.	1.2	5
15	Recent advances in the management of chemotherapy-induced neutropenia: biosimilar granulocyte colony-stimulating factor use in Italy. <i>Future Oncology</i> , 2020, 16, 891-897.	1.1	0
16	Challenges in Post-marketing Studies of Biological Drugs in the Era of Biosimilars: A Report of the International Society for Pharmacoepidemiology 2019 Mid-Year Meeting in Rome, Italy. <i>BioDrugs</i> , 2019, 33, 345-352.	2.2	6
17	In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study. <i>BMC Nephrology</i> , 2019, 20, 359.	0.8	12
18	Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study. <i>Drug Safety</i> , 2019, 42, 1437-1447.	1.4	19

#	ARTICLE	IF	CITATIONS
19	Role of healthcare databases and registries for surveillance of orphan drugs in the real-world setting: the Italian case study. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 497-509.	1.0	24
20	The Role of European Healthcare Databases for Post-Marketing Drug Effectiveness, Safety and Value Evaluation: Where Does Italy Stand?. <i>Drug Safety</i> , 2019, 42, 347-363.	1.4	65
21	Interchangeability of biosimilar and biological reference product: updated regulatory positions and pre- and post-marketing evidence. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 309-315.	1.4	32
22	Pharmacokinetics of new oral anticoagulants: implications for use in routine care. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 1057-1069.	1.5	37
23	Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction. <i>Drug Safety</i> , 2018, 41, 1013-1022.	1.4	38
24	Pattern of Use of Biosimilar and Originator Somatropin in Italy: A Population-Based Multiple Databases Study During the Years 2009â€“2014. <i>Frontiers in Endocrinology</i> , 2018, 9, 95.	1.5	17
25	How did the Introduction of Biosimilar Filgrastim Influence the Prescribing Pattern of Granulocyte Colony-Stimulating Factors? Results from a Multicentre, Population-Based Study, from Five Italian Centres in the Years 2009â€“2014. <i>BioDrugs</i> , 2016, 30, 295-306.	2.2	30
26	Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study. <i>PLoS ONE</i> , 2016, 11, e0155805.	1.1	27
27	Association of Individual Non-Steroidal Anti-Inflammatory Drugs and Chronic Kidney Disease: A Population-Based Case Control Study. <i>PLoS ONE</i> , 2015, 10, e0122899.	1.1	62
28	How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009â€“2013. <i>BioDrugs</i> , 2015, 29, 275-284.	2.2	46
29	The Burden of Nephrotoxic Drug Prescriptions in Patients with Chronic Kidney Disease: A Retrospective Population-Based Study in Southern Italy. <i>PLoS ONE</i> , 2014, 9, e89072.	1.1	50
30	Chronic Kidney Disease Requiring Healthcare Services: A New Approach to Evaluate Epidemiology of Renal Disease. <i>BioMed Research International</i> , 2014, 2014, 1-6.	0.9	14